What Happens in Vegas: PEP to PrEP Opportunities
What Happens in Vegas: Identifying Opportunities to Expand an HIV Prevention Network to Improve PEP and PrEP Delivery
調査の概要
詳細な説明
The primary objective of this study is to assess the rate of engagement in a PEP to PrEP HIV provider network for those patients presenting following a non-occupational HIV exposure.
The development of a referral network and intensive clinical follow up of PEP patients will result in more patients appropriately initiating PEP, being referred to appropriate follow up, and post exposure transition and maintaining on PrEP (if indicated) at completion of the PEP medications.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89104
- 募集
- Huntridge Family Clinic
-
コンタクト:
- John (Rob) Phoenix, APRN
- 電話番号:702-979-1111
- メール:jphoenixaprn@gmail.com
-
主任研究者:
- John Phoenix, APRN
-
主任研究者:
- Christina Madison, PharmD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
HIV negative Men, Women, Transgender Men, Transgender Women age who self identify as having had an actual or perceived non-occupational exposure to HIV
HIV negative Men, Women, Transgender Men, Transgender Women age who self identify at risk of acquisition of HIV after having had an actual or perceived non-occupational exposure to HIV
説明
Inclusion Criteria:
- Actual or perceived non-occupational exposure to HIV, by self report, within 72 hours of enrollment and referred for care
- able and willing to provide informed consent
- available for 12 months of post expoure follow-up Southern Nevada Ryan White defined service area
Exclusion Criteria:
- HIV+ at time of screeing via 4th genderation (Antibody/Antigen) testing
- Current PEP and/or PrEP product condrainidications as listed in the medication product insert.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
rate of engagement
時間枠:from enrollment to day 90
|
Assess the rate of engagement in a PEP to PrEP HIV prevention provider network for those patients presenting following a non-occupational HIV exposure
|
from enrollment to day 90
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
characteristics
時間枠:from enrollment through end of study for all participants
|
Describe the characteristics of patients successfully engaging in HIV prevention via a patient collected survey using a qualtric survey.
|
from enrollment through end of study for all participants
|
|
barriers
時間枠:from enrollment through end of study for all participants
|
Identify and assess barriers to access to HIV prevention care including PEP in the period immediately following HIV exposure from a patient collected survey using a qualtric survey tool
|
from enrollment through end of study for all participants
|
|
Network characteristics
時間枠:from enrollment through end of study for all participants
|
Analyze the network characteristics that faciliate engagement in HIV prevention services from a patient collected survey using a qualtric survey tool
|
from enrollment through end of study for all participants
|
|
transition barriers
時間枠:from enrollment through end of study for all participants
|
Determine and assess to transitioning from PEP to PrEP from a patient collected survey using a qualtric survey tool
|
from enrollment through end of study for all participants
|
|
Retention
時間枠:from enrollment through end of study for all participants
|
Compare and contrast the barriers to access and ongoing retention to PrEP from a patient collected survey using a qualtric survey tool.
|
from enrollment through end of study for all participants
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HFC018001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。